Advertisement

Journal of Radioanalytical and Nuclear Chemistry

, Volume 319, Issue 1, pp 263–269 | Cite as

Synthesis of deuterium-labeled (3R, 5S)-fluvastatin and (3S, 5R)-fluvastatin

  • Mei He
  • Jian Li
  • Lei TianEmail author
Article
  • 13 Downloads

Abstract

In order to comprehensively understanding the metabolism process of fluvastatin, the stable isotope-labeled (3R, 5S)-fluvastatin and (3S, 5R)-fluvastatin were required. Both of (3R, 5S)-fluvastatin and (3S, 5R)-fluvastatin were synthesized via a seven steps procedure starting from aniline and [2H6] 2-bromopropane. Two versions of deuterium labeled compound revealed over 98% deuterium enrichment, using as an internal standard.

Keywords

Deuterium-labeled Fluvastatin Coronary artery disease Synthesis Enantiomers 

Notes

Funding

Funding was provided by National Natural Science Foundation of China (Grant No. 41472124), PetroChina Innovation Foundation (Grant Nos. 2015D-5006-0210 and 2016D-5007-0702) and Nature Science Foundation of Hubei Province (Grant No. 2016CFB178).

References

  1. 1.
    W. H. O. Report (2018) The top 10 causes of death. http://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death. Accessed 24 May 2018
  2. 2.
    Stamler J (1978) Dietary and serum lipid in the multifactorial etiology of atherosclerosis. Arch Surg 113:21–25CrossRefGoogle Scholar
  3. 3.
    Rodwell VW, Nordstrom LJ, Mitschellen JJ (1976) Regulation of HMG-CoA reductase. Adv Lipid Res 14:1–74CrossRefGoogle Scholar
  4. 4.
    Wierzbicki SA (2001) Synthetic statins: more data on newer lipid-lowering agents. Curr Med Res Opin 17:74–77CrossRefGoogle Scholar
  5. 5.
    Kathawala F (1991) HMG-CoA reductase inhibitors: an exciting development in the treatment of hyperlipoproteinemia. Med Res Rev 11:121–146Google Scholar
  6. 6.
    Korhonva M, Doricakova A, Dvorak Z (2015) Optical isomer of atorvastatin, rosuvastatin and fluvastatin enantiospecifically activate pregane X receptor PXR and induce CYP2A6, CYP2B6 and CYP3A4 in human hepatocytesp. PLoS ONE 10:e0137720CrossRefGoogle Scholar
  7. 7.
    Richter RC, Young H, Richter VS et al (2018) Fluvastatin protects cochleae from damage by high-level noise. Sci Rep 8:3033CrossRefGoogle Scholar
  8. 8.
    Liang D, Li S, Zhang M et al (2014) Synthesis of a diastereomeric mixture of deuterium-labeled lovastatin and its acid ammonium salt. J Radioanal Nucl Chem 300:891–894CrossRefGoogle Scholar
  9. 9.
    Tian L, Tao J, Chen L (2011) Synthesis of deuterium-labeled simvastatin. J Label Compd Radiopharm 54:625–628CrossRefGoogle Scholar
  10. 10.
    Chavan BB, Kalariya DP, Nimbalkar DR et al (2017) Identification and characterization of fluvastatinmetabolites in rats by UHPLC/Q-TOF/MS/MS and in silico toxicological screening ofthe metabolites. J Mass Spectrom 52:296–314CrossRefGoogle Scholar
  11. 11.
    Tang ST, Jones L, Sunay BU (1998) Synthesis of carbon-14 labeled fluvastatin. J Label Compd Radiopharm 41(1):1–7CrossRefGoogle Scholar
  12. 12.
    Ohtawa M, Masuda N, Akasaka I et al (1999) Cell uptake of fluvastatin, an inhibitor of HMG-CoA reductase, by rat cultured hepatocytes and human aortic endothelial cells. Br J Clin Pharmacol 47:383–389CrossRefGoogle Scholar
  13. 13.
    Masuda N, Akasaka I, Ohtawa M et al (1995) Metabolic fate of fluvastatin, an inhibitor of HMG-CoA reductase(1): absorption, distribution and excretion of [14C] fluvastatin after single administration in rats. Drug Metab Pharmacokinet 10:513–528CrossRefGoogle Scholar
  14. 14.
    Masuda N, Akasaka I, Ohtawa M et al (1995) Metabolic fate of fluvastatin, an inhibitor of HMG-CoA reductase(2): transfer to the fetus and milk, and absorption, distribution and excretion after consecutive oral administration of [14C] fluvastatin in rats. Drug Metab Pharmacokinet 10:529–546CrossRefGoogle Scholar
  15. 15.
    Fuenfschilling CP, Hoehm P, Mutz J (2007) An improved manufacturing process for fluvastatin. Org Process Res Dev 11:13–18CrossRefGoogle Scholar
  16. 16.
    Koftis TV, Panagiotidis T, Soni RR et al (2011) Improved process for the preparation of fluvastatin and salts thereof. WO2010118757A1. Accessed 21 Oct 2010Google Scholar
  17. 17.
    Chen K, Hardtmann GE, Lee GT Preparation of olefinic compounds. EP 0244346A2. Accessed 4 Nov 1987Google Scholar
  18. 18.
    Fachini M Process for the preparation of fluvastatin sodium salt. US7662848 B2. Accessed 16 Feb 2010Google Scholar
  19. 19.
    Zacharia TJ, Tanaka T, Hayashi M (2010) Facile and highly enantioselective synthesis of (+)-and (-)-fluvastatin and their analogues. J Org Chem 75:7514–7518CrossRefGoogle Scholar
  20. 20.
    Tempkin O, Abel S, Chen C et al (1997) Asymmetric synthesis of 3, 5-dihydroxy-6(E) -heptenoatecontaining HMG-CoA reductase inhibitors. Tetrahedron 53:10659–10670CrossRefGoogle Scholar
  21. 21.
    Kathawala GF Intermediates in the synthesis of indole analogs of mevalonolactone and derivatives thereof. US 4739073. Accessed 19 Apr 1988Google Scholar
  22. 22.
    Jonathan WW, John AK (1941) Ketene dimer. Org Synth 21:64CrossRefGoogle Scholar
  23. 23.
    Braun M, Devant R (1984) Tetrahedron Lett 25:5031–5034CrossRefGoogle Scholar

Copyright information

© Akadémiai Kiadó, Budapest, Hungary 2018

Authors and Affiliations

  1. 1.School of Resources and EnvironmentYangtze UniversityWuhanPeople’s Republic of China
  2. 2.School of Biochemical and Environmental EngineeringNanjing Xiaozhuang UniversityNanjingPeople’s Republic of China
  3. 3.School of Petroleum EngineeringYangtze UniversityWuhanPeople’s Republic of China

Personalised recommendations